OBJECTIVE: This study examined the effect of adjunctive intranasal insulin therapy on body metabolism in patients with schizophrenia. METHOD: Each subject had a DSM-IV diagnosis of schizophrenia or schizoaffective disorder and had been on stable dose of antipsychotic agent for at least one month. In an 8-week randomized, double-blind, placebo-controlled study, subjects received either intranasal insulin (40 IU 4 times per day) or placebo. The whole body dual-energy X-ray absorptiometry (DXA) was used to assess body composition. Lipid particles were assessed using nuclear magnetic resonance (NMR) spectroscopy. All assessments were conducted at baseline, and repeated at week 8. RESULTS:A total number of 39 subjects completed the study (18 in the insulin group, 21 in the placebo group). There were no significant differences between the two groups in week 8 changes for body weight, body mass index, waist circumference, as well as various measures of lipid particles (p's>0.100). The DXA assessment showed no significant differences between the two groups in week 8 changes for fat mass, lean mass or total mass (p's>0.100). CONCLUSION: In the present study, adjunctive therapy of intranasal insulin did not seem to improve body metabolism in patients with schizophrenia. The implications for future studies were discussed.
RCT Entities:
OBJECTIVE: This study examined the effect of adjunctive intranasal insulin therapy on body metabolism in patients with schizophrenia. METHOD: Each subject had a DSM-IV diagnosis of schizophrenia or schizoaffective disorder and had been on stable dose of antipsychotic agent for at least one month. In an 8-week randomized, double-blind, placebo-controlled study, subjects received either intranasal insulin (40 IU 4 times per day) or placebo. The whole body dual-energy X-ray absorptiometry (DXA) was used to assess body composition. Lipid particles were assessed using nuclear magnetic resonance (NMR) spectroscopy. All assessments were conducted at baseline, and repeated at week 8. RESULTS: A total number of 39 subjects completed the study (18 in the insulin group, 21 in the placebo group). There were no significant differences between the two groups in week 8 changes for body weight, body mass index, waist circumference, as well as various measures of lipid particles (p's>0.100). The DXA assessment showed no significant differences between the two groups in week 8 changes for fat mass, lean mass or total mass (p's>0.100). CONCLUSION: In the present study, adjunctive therapy of intranasal insulin did not seem to improve body metabolism in patients with schizophrenia. The implications for future studies were discussed.
Authors: Deborah J Clegg; Christine A Riedy; Kathleen A Blake Smith; Stephen C Benoit; Stephen C Woods Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Michael W Schwartz; Stephen C Woods; Randy J Seeley; Gregory S Barsh; Denis G Baskin; Rudolph L Leibel Journal: Diabetes Date: 2003-02 Impact factor: 9.461
Authors: Pavla Stopkova; Takuya Saito; Demitri F Papolos; Jan Vevera; Ivo Paclt; Ilja Zukov; Yonina B Bersson; Benjamin A Margolis; Rael D Strous; Herbert M Lachman Journal: Biol Psychiatry Date: 2004-05-15 Impact factor: 13.382
Authors: Stephen C Benoit; Ellen L Air; Lique M Coolen; Richelle Strauss; Alana Jackman; Deborah J Clegg; Randy J Seeley; Stephen C Woods Journal: J Neurosci Date: 2002-10-15 Impact factor: 6.167
Authors: Xiaoduo Fan; Ellen J Anderson; Paul M Copeland; Christina P Borba; Dana D Nguyen; Oliver Freudenreich; Donald C Goff; David C Henderson Journal: Biol Psychiatry Date: 2006-08-22 Impact factor: 13.382
Authors: Dawn L Thiselton; Vladimir I Vladimirov; Po-Hsiu Kuo; Joseph McClay; Brandon Wormley; Ayman Fanous; Francis A O'Neill; Dermot Walsh; Edwin J C G Van den Oord; Kenneth S Kendler; Brien P Riley Journal: Biol Psychiatry Date: 2007-09-06 Impact factor: 13.382
Authors: Sri Mahavir Agarwal; Nicolette Stogios; Zohra A Ahsan; Jonathan T Lockwood; Markus J Duncan; Hiroyoshi Takeuchi; Tony Cohn; Valerie H Taylor; Gary Remington; Guy E J Faulkner; Margaret Hahn Journal: Cochrane Database Syst Rev Date: 2022-10-03
Authors: Johanna Taylor; Brendon Stubbs; Catherine Hewitt; Ramzi A Ajjan; Sarah L Alderson; Simon Gilbody; Richard I G Holt; Prakash Hosali; Tom Hughes; Tarron Kayalackakom; Ian Kellar; Helen Lewis; Neda Mahmoodi; Kirstine McDermid; Robert D Smith; Judy M Wright; Najma Siddiqi Journal: PLoS One Date: 2017-01-05 Impact factor: 3.240
Authors: Pruntha Kanagasundaram; Jiwon Lee; Femin Prasad; Kenya A Costa-Dookhan; Laurie Hamel; Madeleine Gordon; Gary Remington; Margaret K Hahn; Sri Mahavir Agarwal Journal: Front Psychiatry Date: 2021-03-17 Impact factor: 4.157